@Article{Sobczak2020,
journal="Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii",
issn="1234-8279",
volume="36",
number="1",
year="2020",
title="Lithium pharmacogenetics. Two decades of studies",
abstract="Pharmacogenetic research aims to elucidate associ ations of genetic variants and individual effects of pharmacotherapy. Personalised expected response to medications might be useful in prognosis for polygen etically determined disorders. In bipolar disorder (BP), that is partly hereditary polygenic disorder, a subgroup of patients excellently responding to lithium prophy laxis was described. During the last 20 years molecular technology allowed to investigate genome of patients treated with lithium and candidate association studies characterised them more precisely than clinical fea tures. The role of several neurotransmitters’ pathways, second messengers, neuroprotection involved genes and clock genes associations were discovered. Further lab oratory technics development enables us to perform genome-wide association studies (GWAS) and polygenic risk score (PRS) analyses. We aimed to review research on genes involved in lithium treatment efficacy and safe ty. PubMed for English papers, articles published in Pol ish and reference lists from full-text available papers were searched. Pharmacogenetic findings for lithium treatment effects might help develop new personalised strategies and consequently better symptom reduction. So far, chronicity and recurrent course of bipolar dis order impair the functioning of numerous patients and strongly increase the risk of suicide.",
author="Sobczak, Maciej
and Pawlak, Joanna",
pages="67--82",
url="https://www.termedia.pl/Lithium-pharmacogenetics-Two-decades-of-studies,164,45805,1,1.html"
}